Skip to main content
x
Dartmouth-Hitchcock logo
Summer Flowers In This Section

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

Principal Investigator

Jonathan Glass

Study Number

F18135

Summary

Primary Objective is to evaluate the clinical efficacy of oral apremilast 30 mg twice daily (BID), compared to placebo, in subjects with moderate to severe genital psoriasis during the 16-week Placebo-controlled Phase.

Phase

Phase III

Contact

Debra Rodgers

Available at the following location(s)

  • Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms

0